Company Overview and News
Oracle reports adjusted earnings of 99 cents a share on sales of $11.25 billion, beating expectations
WFCNP WFC.PRL WFC.PRJ MXWL WFC.PRT WFC.PRR WFC.PRQ FEYE WFC.PRP WFC.PRO WFC.PRN WFC.PRY GEN WFC.PRX WFC.PRW ORCL WFC.PRV DIS ETSY WFC IBM WFC.WS GEC GE XLK DQ OCLCF GNE
Unless you’ve been living under a rock, you know that the narrative surrounding broad markets — it’s been one of strife since late January until the recent rally. Volatility spiked and the S&P 500 Index still sits almost 3% below late-January highs.
LRCX TEVA GS.PRB GS.PRA CDNS DLTR GLSSP FEYE AMZN ALXN AMAT CELG AVGO EBAY SNAP JBK QQQ TTWO TFG VRX CHKP CA CTSH MAR GS.PRJ GS.PRI BABA EXPE ORBK GOOGL GS.PRD GS.PRC QCOM GS.PRN GS.PRK JD XLNX FB ULTA ADP MNST TEVVF PYPL NFLX AMD NVDA GOOG KLAC ATVI MAR.WI GS MYL AAPL KO PAYX IBM EA CELGZ GSC GS.PRICL PANW GSJ BKNG ADPVV TEVJF MU DG MNK BRCM GJS
The cyber-security industry has been putting up an impressive show on the bourse, of late, with the slew of cyber attacks, over the past few months, playing the supporting role. Cisco Systems, Inc.’s (NASDAQ:CSCO) latest report hints at another attack hovering over Ukraine, once again, which might cause a complete blackout in the country.
PFPT FEYE EFX PANW CSCO NTGR
Cybersecurity has become an increasingly important issue that companies have to address as they continue to develop new platforms and mobile apps. Hackers have been able to steal credit card and personal information from major companies like Equifax, JPMorgan and Home Depot. As a result, cybersecurity has become more necessary, and instead of developing a dedicated department within a company, most opt to hire a third-party cybersecurity firm.
CYBR HD FEYE PANW CHKP FTNT
A third-quarter earnings beat by Palo Alto Networks Inc. (NASDAQ:PANW), a cloud-based security company, was overshadowed by its hiring of Nikesh Arora as its next CEO. Arora has an impressive resume, having held C-suite positions at both Alphabet Inc’s (NASDAQ:GOOG, NASDAQ:GOOGL) Google and Softbank Group Corp. (OTCMKTS:SFTBY), where he was once considered heir-apparent to CEO Masayoshi Son.
CYBR FEYE GOOGL PANW CSCO GOOG SFTBF 9984 CUDA SFTBY FTNT
As the CEO transitions to the role of vice chairman of the board, Palo Alto Networks (PANW) trades close to all-time highs. Analysts recently turned increasingly bullish on the stock and raised price targets following FQ3 earnings, but revenue growth flipping back to a decelerating trend is a bad signal for the stock.
FEYE IMPV PANW
Surprise! Palo Alto Networks Inc (NYSE:PANW) shareholders who were prepping for a post-close earnings report from the cybersecurity outfit were thrown something of a curveball on Monday. Breaking from tradition, the company dished out its fiscal Q3 numbers on Monday morning instead.
FEYE GOOGL PANW CHKP GOOG 9984 SFTBF SFTBY
It has been about a month since the last earnings report for FireEye, Inc. (FEYE - Free Report) . Shares have lost about 10.2% in that time frame.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The cyber-security industry has been putting up an impressive show on the bourse, of late, with the slew of cyber attacks, over the past few months, playing the supporting role. Cisco’s (CSCO - Free Report) latest report hints at another attack hovering over Ukraine, once again, which might cause a complete blackout in the country. Per the findings of Talos — a cyber-intelligence unit of Cisco — hackers have infected more than 500,000 routers and storage devices across 54 nations.
PFPT FEYE EFX PANW NTGR
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to FEYE / FireEye, Inc. on message board site Silicon Investor.
as of ET